54 related articles for article (PubMed ID: 19492147)
1. Evaluation of optical coherence tomography for the measurement of the effects of activators and anticoagulants on the blood coagulation in vitro.
Xu X; Geng J; Liu G; Chen Z
IEEE Trans Biomed Eng; 2013 Aug; 60(8):2100-6. PubMed ID: 23392340
[TBL] [Abstract][Full Text] [Related]
2. Carbonization of quercetin into nanogels: a leap in anticoagulant development.
Chu HW; Chen WJ; Liu KH; Mao JY; Harroun SG; Unnikrishnan B; Lin HJ; Ma YH; Chang HT; Huang CC
J Mater Chem B; 2024 Jun; 12(22):5391-5404. PubMed ID: 38716492
[TBL] [Abstract][Full Text] [Related]
3. WEDGE: an anticoagulant thrombin mutant produced by autoactivation.
Wood DC; Pelc LA; Pozzi N; Wallisch M; Verbout NG; Tucker EI; Gruber A; Di Cera E
J Thromb Haemost; 2015 Jan; 13(1):111-4. PubMed ID: 25369995
[TBL] [Abstract][Full Text] [Related]
4. Using photons to manipulate enzyme inhibition by an azobenzene-modified nucleic acid probe.
Kim Y; Phillips JA; Liu H; Kang H; Tan W
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6489-94. PubMed ID: 19359478
[TBL] [Abstract][Full Text] [Related]
5. Electrochemical Monitoring in Anticoagulation Therapy.
Mruthunjaya AKV; Torriero AAJ
Molecules; 2024 Mar; 29(7):. PubMed ID: 38611733
[TBL] [Abstract][Full Text] [Related]
6. A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model.
Krissanaprasit A; Mihalko E; Meinhold K; Simpson A; Sollinger J; Pandit S; Dupont DM; Kjems J; Brown AC; LaBean TH
Mol Ther; 2024 May; ():. PubMed ID: 38720458
[TBL] [Abstract][Full Text] [Related]
7. Development of supramolecular anticoagulants with on-demand reversibility.
Dockerill M; Ford DJ; Angerani S; Alwis I; Dowman LJ; Ripoll-Rozada J; Smythe RE; Liu JST; Pereira PJB; Jackson SP; Payne RJ; Winssinger N
Nat Biotechnol; 2024 Apr; ():. PubMed ID: 38689027
[TBL] [Abstract][Full Text] [Related]
8. Oral anticoagulants for Asian patients with atrial fibrillation.
Sabir I; Khavandi K; Brownrigg J; Camm AJ
Nat Rev Cardiol; 2014 May; 11(5):290-303. PubMed ID: 24614113
[TBL] [Abstract][Full Text] [Related]
9. Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria.
Neve EP; Nordling A; Andersson TB; Hellman U; Diczfalusy U; Johansson I; Ingelman-Sundberg M
J Biol Chem; 2012 Feb; 287(9):6307-17. PubMed ID: 22203676
[TBL] [Abstract][Full Text] [Related]
10. New anticoagulants - promising and failed developments.
Harenberg J; Marx S; Krejczy M; Wehling M
Br J Pharmacol; 2012 Jan; 165(2):363-72. PubMed ID: 21740405
[TBL] [Abstract][Full Text] [Related]
11. Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
Schützer KM; Svensson MK; Zetterstrand S; Eriksson UG; Wåhlander K
Eur J Clin Pharmacol; 2010 Sep; 66(9):903-10. PubMed ID: 20535457
[TBL] [Abstract][Full Text] [Related]
12. Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.
Walfridsson H; Johansson B; Englund A; Kennebäck G; Schwieler J; Kongstad O; Wåhlander K; Malm AR; Edvardsson N
Clin Drug Investig; 2010; 30(7):461-71. PubMed ID: 20528001
[TBL] [Abstract][Full Text] [Related]
13. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY; Rasmussen LH; Olsson SB; Jensen EC; Persson AL; Eriksson U; Wåhlander KF;
Eur Heart J; 2009 Dec; 30(23):2897-907. PubMed ID: 19690349
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
Deinum J; Mattsson C; Inghardt T; Elg M
Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Lip GY; Rasmussen LH; Olsson SB; Jensen E; Hamrén B; Eriksson UG; Wåhlander K
Br J Clin Pharmacol; 2015 Dec; 80(6):1362-73. PubMed ID: 26174611
[TBL] [Abstract][Full Text] [Related]
17. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
Mattsson C; Sarich TC; Carlsson SC
Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
